VCYT - Veracyte, Inc.
After hours:
| Previous close | 25.90 |
| Open | 26.21 |
| Bid | 24.80 x 1000 |
| Ask | 27.03 x 1200 |
| Day's range | 25.42 - 26.21 |
| 52-week range | 14.92 - 32.40 |
| Volume | |
| Avg. volume | 671,682 |
| Market cap | 1.871B |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
SOUTH SAN FRANCISCO, Calif., May 25, 2023--New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
- Business Wire
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
SOUTH SAN FRANCISCO, Calif., May 24, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.
- Business Wire
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 23, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences:
- Business Wire
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
SOUTH SAN FRANCISCO, Calif., May 12, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test –
- Business Wire
Veracyte Announces First Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., May 04, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023.
- Business Wire
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
SOUTH SAN FRANCISCO, May 04, 2023--New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
- Business Wire
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
SOUTH SAN FRANCISCO, Calif., May 03, 2023--New data published in Cancer suggest Decipher GRID-derived gene expression signature could enable more personalized prostate cancer treatment
- Business Wire
Veracyte Announces Release of Inaugural ESG Report
SOUTH SAN FRANCISCO, Calif., May 03, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report. The 2023 ESG Report sets the foundation for Veracyte’s ESG performance and outlines the company’s ambitions to build upon its progress in the years ahead.
- Business Wire
Data Published in "The Red Journal" Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
SOUTH SAN FRANCISCO, Calif., May 02, 2023--Published Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Intermediate-Risk Prostate Cancer
- Business Wire
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
SOUTH SAN FRANCISCO, Calif., May 01, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C.
- Business Wire
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
SOUTH SAN FRANCISCO, Calif., April 29, 2023--Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
- Business Wire
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 27, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstracts leverage Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) database to explore potential opportunities for further personalizing treatme
- Business Wire
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
SOUTH SAN FRANCISCO, Calif., April 17, 2023--Data Show Veracyte’s Decipher Prostate Genomic Classifier Can Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
- Business Wire
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
SOUTH SAN FRANCISCO, Calif., April 13, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
- Business Wire
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 12, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company’s Decipher Prostate Genomic
- Business Wire
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
SOUTH SAN FRANCISCO, Calif., March 15, 2023--Veracyte Announces Abstracts to Be Presented at AACR Annual Meeting Highlighting Company's Multi-Omics Capabilities & Tools for Biopharma Partners
- Business Wire
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
SOUTH SAN FRANCISCO, Calif., March 11, 2023--Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB).
- Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., February 22, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022.
- Business Wire
Data Published in "The Red Journal" Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
SOUTH SAN FRANCISCO, Calif., February 15, 2023--Data Published in The Red Journal Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
- Business Wire
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
SOUTH SAN FRANCISCO, Calif., February 13, 2023--New data to be presented at 2023 ASCO GU suggest Veracyte's Decipher GRID database can help personalize prostate cancer treatment
- Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
SOUTH SAN FRANCISCO, Calif., February 06, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
- Business Wire
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
SOUTH SAN FRANCISCO, Calif., February 01, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.
- Business Wire
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
SOUTH SAN FRANCISCO, Calif., February 01, 2023--Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
- Business Wire
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif., December 15, 2022--Data published in JCEM demonstrate strong real-world performance of Veracyte’s Afirma GSC in thyroid cancer diagnosis
- Business Wire
Veracyte Announces Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., November 02, 2022--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022.
